NeuroPace NPCE
NASDAQ NPCE
$14.50 -0.26 (-1.76%)
As of: Sep 9, 2026 · 3:59 PM EDT

NeuroPace (NPCE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)

Analysis

NeuroPace (NPCE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn -47.84%
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn 23.94%
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn 41.36%
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn 44.34%
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn 13.80%
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn -27.18%
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn -
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn 38.54%
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn 12.92%
10 NeuroPace 493.15 Mn 441.45 Mn 18.91 Mn 24.57%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 24.57%
Mar 31, 2026 -0.26%
Dec 31, 2025 47.15%
Sep 30, 2025 36.91%
Jun 30, 2025 -6.96%
Mar 31, 2025 27.51%
Dec 31, 2024 20.12%
Sep 30, 2024 23.07%
Jun 30, 2024 17.43%
Mar 31, 2024 6.09%
Dec 31, 2023 41.23%
Sep 30, 2023 36.89%
Jun 30, 2023 26.65%
Mar 31, 2023 16.58%
Dec 31, 2022 -2.89%
Sep 30, 2022 -47.26%
Jun 30, 2022 -97.63%
Mar 31, 2022 -101.12%
Dec 31, 2021 -119.80%
Sep 30, 2021 -100.43%